Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.80 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mofezolac SCHEMBL151701 | 0.89 | PTGS2 (1.00) | PTGS2PTGS1PDE3A | |
| SCHEMBL9124704 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1PDE3A | |
| SCHEMBL19537395 | 0.88 | PTGS2 (0.78) | PTGS2PTGS1PDE3A | |
| Mofezolac SCHEMBL5398805 | 0.88 | PTGS2 (0.97) | PTGS2PTGS1PDE3A | |
| SCHEMBL15943678 | 0.86 | PTGS2 (0.76) | PTGS2PTGS1PDE3A | |
| SCHEMBL23021598 | 0.85 | PTGS2 (0.80) | PTGS2PTGS1PDE3A | |
| SCHEMBL20904217 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1PDE3A | |
| SCHEMBL13875301 | 0.85 | PTGS2 (0.74) | PTGS2PTGS1PDE3A | |
| SCHEMBL10333569 | 0.84 | PTGS2 (0.73) | PTGS2PTGS1PDE3A | |
| SCHEMBL19537413 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802726-B2 | Use of nitrooxyderivative of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2014-08-12 | — | — | US | disclosed |
| US-8575222-B2 | Use of nitrooxyderivatives of drug for the treatment of muscular dystrophies | NICOX S.A. (FR) | 2013-11-05 | — | — | US | disclosed |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | NICOX SA (FR) | 2009-04-09 | — | — | US | disclosed |
| WO-2007088123-A2 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | NICOX S.A. (FR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093510-A1 | Use of Nitrooxyderivatives of Drug for the Treatment of Muscular Dystrophies | TNNC1, CPT1B, SMN1; SMN2 | PTGS2 440/4885PTGS1 292/4885PDE3A 15/4885 |
| US-20130137765-A1 | USE OF NITROOXYDERIVATIVE OF DRUG FOR THE TREATMENT OF MUSCULAR DYSTROPHIES | TNNC1, CPT1B, SMN1; SMN2 | PTGS2 489/4885PTGS1 248/4885PDE3A 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.